



TEVA PHARMACEUTICAL INDUSTRIES LTD.




CONTACT INFORMATION: **Elana Holzman** Tel +972-3-926-7554, E-mail: [elana.holzman@teva.co.il](mailto:elana.holzman@teva.co.il) **Kevin Mannix** Tel (215) 591-8912, E-mail: [kevin.mannix@tevausa.com](mailto:kevin.mannix@tevausa.com)

## COMPANY OVERVIEW

Teva Pharmaceutical Industries Ltd., is among the top 20 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in over 60 countries with some 36,600 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis),

autoimmune diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.

## NET SALES (U.S. \$ in Millions)




## MARKET DATA (As of Nov. 2, 2009)


Stock Symbol	TEVA
Closing Price	\$51.19
52 Week Range	\$39.75 - \$54.95
Market Capitalization	\$44.74 billion
# 10 in NASDAQ-100	




## NET INCOME<sup>(1,2)</sup> (U.S. \$ in Millions)




## STOCK CHART (As of Nov. 2, 2009)



## EARNING PER SHARE<sup>(1,2,3)</sup> (U.S. \$ in Millions)



## R&D EXPENSES (NET) (U.S. \$ in Millions)



(1) reflect non - GAAP results. (2) Reflects retroactive adjustment following the adoption of APB14-1. (3) Reflects the 2:1 stock splits (June 2004)



TEVA PHARMACEUTICAL INDUSTRIES LTD.

## RECENT EVENTS

**October 20, 2009** - Teva announced that MediWound, a company in which Teva holds an 11% interest, reported positive results from an interim analysis of a phase III trial for Debrase®, for the treatment of burns. MediWound expects to submit an application for marketing authorization in Europe during 2010.

**October 16, 2009** - Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals and Natco Pharma for patent infringement in connection with an ANDA containing a Paragraph IV certification for Copaxone® filed with the FDA by these companies.

**September 24, 2009** - Teva announced today the U.S. District Court for the Southern District of Indiana has issued a decision invalidating 2 patents for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets. In the same opinion, the Court rejected Teva's challenges to 4 earlier expiring patents. Based on this ruling, the Court enjoined Teva from commencing the commercial launch of its generic product prior to the expiration date of those patents. Teva plans to appeal the decision.

**September 23, 2009** - Results from the ADAGIO trial, published in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving AZILECT®

at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group). This finding is consistent with a possible disease-modifying effect for AZILECT®.

**August 19, 2009** - Teva announced that the U.S. District Court for the District of New Jersey has issued a decision in its litigation over the Company's ANDA to market its generic version of Merck's Singulair® (montelukast sodium) Tablets, holding the patent valid and enforceable. Teva is currently reviewing the Court's decision.


**August 11, 2009** - Teva announced the approval and launch of Sanofi-Aventis' Eloxatin® (oxaliplatin injection). Eloxatin® had annual sales of ~\$1.3 billion in the U.S. for the 12 months ended December 31, 2008, based on IMS data. Sanofi-Aventis has filed a motion for a preliminary injunction, and oral argument will be heard on November 17, 2009.

**August 5, 2009** - Teva announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a ruling finding Bayer Schering's U.S. Patent No. 6,787,531 invalid. The patent is listed in the Orange Book for Bayer's oral contraception Yasmin®.

## SALES BY REGION

Q3/09: \$3.55 Billion

North America	63%
Europe <sup>(1)</sup>	23%
Latin America <sup>(2)</sup>	5%
Israel	3%
CEE	4%
ROW	2%




(1) Includes EU member states, Switzerland & Norway  
(2) Includes Mexico

## U.S. GENERIC PIPELINE (As of October 23, 2009)

**210** ANDAs -  
Over **\$113** billion in total branded sales  
**136** Paragraph IV Filings  
**83** First-To-File  
Over **\$54** Billion In Total Branded Sales

## COPAXONE® - GLOBAL IN-MARKET SALES (U.S. \$ in Millions)



## PROPRIETARY BRANDED PHARMACEUTICALS - PIPELINE

Marketed products	End of Phase III 2009-2012	End of Phase III beyond 2012
Copaxone® Multiple Sclerosis	Laquinimod - Oral Multiple Sclerosis (Phase III)	Laquinimod - Crohn's disease (Phase II)
Azilect® Parkinson's	Talampanel - ALS (Phase II)	Laquinimod - Lupus (Phase I)
QVAR® Inhaled Steroid	Pagoclone - Stuttering (Phase III)	TV-1102 - Multiple Sclerosis (Phase II)
ProAir® Inhaled short acting beta-mimetic	Debrase - Burns (Phase III)	Pagoclone - Stuttering (Phase II)
Easi-Breathe products Asthma & COPD	StemEx® - Hemato-oncological (Phase III)	Talampanel - Glioblastoma (Phase II)
Seasonique® / LoSeasonique™ Contraception	BDP HFA Nasal - Respiratory (Phase III)	TV-1390 - Multiple Sclerosis (Phase I)
Plan B® One-Step Emergency Contraception	DR-1-3 - Contraception (Phase II)	DiaPep-277 - Type I Diabetes (Phase III)
ParaGard® Intrauterine Contraception	Oxybutynin Vaginal Ring Overactive Bladder (Phase II)	CT-011 - Hemato-Oncological (Phase II)
TEV-TROPIN® Growth Hormone Deficiency	Progesterone Ring - Infertility (Phase II)	CT-011 - Solid Tumor Oncology (Phase II)
TevaGrastim® Hematology	Neugranin - Hematology (Phase II)	

## SELECTED GENERIC APPROVALS U.S. AUGUST-OCTOBER 2009

Product	Approval/ Launch Date	Branded Product		Indication	
		Name	Market size (U.S. \$ in Millions)		
Bicalutamide <sup>(1)</sup>	Tablets	6/7/09	Casodex®	322	Metastatic prostate cancer.
Divalproex ER, 500 mg <sup>(1)</sup>	ER Tablets	3/8/09	Depakote®	367	• Anticonvulsant • Bipolar disorder • Prophylaxis of migraine headaches
Triamcinolone Acetonide, 0.055 mg/inhalation	Nasal Spray	3/8/09	Nasacort AQ®	300	Treatment of symptoms of seasonal and perennial allergic rhinitis
Aspirin/Dipyridamole	ER Capsules	14/8/09	Aggrenox®	384	Antiplatelet to reduce the risk of stroke
Temozolamide <sup>(2)(3)</sup>	Capsules	11/9/09	Temodar®	366	Treatment of adult patients with refractory anaplastic astrocytoma
Dorzolamide/Timolol	Ophthalmic Solution	28/9/09	Cosopt®	255	Treatment of open-angle glaucoma or ocular hypertension

1 Launched 2 Exclusivity (180 days) 3 Tentative approval